Aclaris Therapeutics (ACRS) Gains from Investment Securities (2014 - 2026)
Aclaris Therapeutics (ACRS) recorded quarterly Gains from Investment Securities of $184000.0 in Q1 2026, down 54.0% quarter-over-quarter from $400000.0 in Q4 2025, and down 95.23% on a YoY basis from $3.9 million in Q1 2025.
Aclaris Therapeutics (ACRS) Gains from Investment Securities (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Gains from Investment Securities history runs 13 years deep, the most recent figure standing at $184000.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities fell 95.23% year-over-year to $184000.0; the TTM figure through Mar 2026 stood at $2.2 million (down 43.4% YoY), while the FY2025 annual figure was $11.3 million, up 425.67% from the prior year.
- Gains from Investment Securities was $184000.0 for Q1 2026 at Aclaris Therapeutics, down from $400000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $5.0 million in Q2 2022 to a low of -$27.0 million in Q4 2023.
- Historically, Gains from Investment Securities has averaged -$612025.5 across 5 years, with a median of $800000.0 in 2024.
- The sharpest annual moves came in 2023 and 2025: Gains from Investment Securities plunged 2586.37% in 2023, then jumped 650.0% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $1.1 million in 2022, then slumped by 2586.37% to -$27.0 million in 2023, then soared by 95.19% to -$1.3 million in 2024, then surged by 130.77% to $400000.0 in 2025, then tumbled by 54.0% to $184000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $184000.0 (Q1 2026), $400000.0 (Q4 2025), and $100000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Aclaris Therapeutics | 580.93 Mn | 580.93 Mn | 1.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 184,000.00 |
| Mar 31, 2026 | 184,000.00 |
| Dec 31, 2025 | 400,000.00 |
| Dec 31, 2025 | 400,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 1.50 Mn |
| Jun 30, 2025 | 1.50 Mn |
| Mar 31, 2025 | 3.86 Mn |
| Mar 31, 2025 | 3.86 Mn |
| Dec 31, 2024 | -1.30 Mn |
| Dec 31, 2024 | -1.30 Mn |
| Sep 30, 2024 | 800,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Mar 31, 2024 | 1.29 Mn |
| Mar 31, 2024 | 1.29 Mn |
| Dec 31, 2023 | -27.00 Mn |
| Dec 31, 2023 | -27.00 Mn |